These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 35338608)

  • 1. Sodium-glucose cotransporter-2 inhibitors in heart failure: an updated meta-analysis.
    Cao Y; Li P; Li Y; Han Y
    ESC Heart Fail; 2022 Jun; 9(3):1942-1953. PubMed ID: 35338608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.
    Ji PJ; Zhang ZY; Yan Q; Cao HL; Zhao YJ; Yang B; Li J
    ESC Heart Fail; 2023 Apr; 10(2):1314-1325. PubMed ID: 36722326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
    Banerjee M; Maisnam I; Pal R; Mukhopadhyay S
    Eur Heart J; 2023 Oct; 44(37):3686-3696. PubMed ID: 37605637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Singh AK; Singh R
    Diabetes Metab Syndr; 2021; 15(1):351-359. PubMed ID: 33503584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Cosentino F; Cannon CP; Cherney DZI; Masiukiewicz U; Pratley R; Dagogo-Jack S; Frederich R; Charbonnel B; Mancuso J; Shih WJ; Terra SG; Cater NB; Gantz I; McGuire DK;
    Circulation; 2020 Dec; 142(23):2205-2215. PubMed ID: 33026243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
    Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chiang FT; Tu YK
    Eur J Endocrinol; 2023 Jul; 189(1):S17-S25. PubMed ID: 37474112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis.
    Banerjee M; Pal R; Nair K; Mukhopadhyay S
    Indian Heart J; 2023; 75(2):122-127. PubMed ID: 36914068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Systematic Review and Network Meta-Analysis.
    Zafeiropoulos S; Farmakis IT; Milioglou I; Doundoulakis I; Gorodeski EZ; Konstantinides SV; Cooper L; Zanos S; Stavrakis S; Giamouzis G; Butler J; Giannakoulas G
    JACC Heart Fail; 2024 Apr; 12(4):616-627. PubMed ID: 37656079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis.
    Treewaree S; Kulthamrongsri N; Owattanapanich W; Krittayaphong R
    Front Cardiovasc Med; 2023; 10():1046194. PubMed ID: 36824458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit of sodium-glucose cotransporter-2 inhibitors on survival outcome is related to the type of heart failure: A meta-analysis.
    Zhao L; Guo W; Huang W; Wang L; Huang S
    Diabetes Res Clin Pract; 2022 May; 187():109871. PubMed ID: 35413392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
    Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV
    Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials.
    Lu Y; Li F; Fan Y; Yang Y; Chen M; Xi J
    Eur J Intern Med; 2021 May; 87():20-28. PubMed ID: 33824055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis.
    Pandey AK; Dhingra NK; Hibino M; Gupta V; Verma S
    ESC Heart Fail; 2022 Apr; 9(2):942-946. PubMed ID: 35112512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of different sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a network meta-analysis.
    Lan X; Zhu H; Cao Y; Hu Y; Fan X; Zhang K; Wu M
    Front Cardiovasc Med; 2024; 11():1379765. PubMed ID: 38845687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
    Mentz RJ; Brunton SA; Rangaswami J
    Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Zhao Z; Jin P; Zhang Y; Hu X; Tian C; Liu D
    Front Cardiovasc Med; 2022; 9():826684. PubMed ID: 35557542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
    Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
    Am Heart J; 2021 Feb; 232():10-22. PubMed ID: 33214130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ismayl M; Abbasi MA; Al-Abcha A; El-Am E; Lundgren S; Goldsweig AM; Anavekar NS
    Curr Probl Cardiol; 2023 May; 48(5):101597. PubMed ID: 36681210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.
    Kumar K; Kheiri B; Simpson TF; Osman M; Rahmouni H
    Am J Med; 2020 Nov; 133(11):e625-e630. PubMed ID: 32389659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: A meta-analysis of randomized controlled trials.
    Li X; Zhang Q; Zhu L; Wang G; Ge P; Hu A; Sun X
    Int J Cardiol; 2021 Jun; 332():119-126. PubMed ID: 33838152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.